Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
|
|
VIVUS INC (VVUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/06/2020 |
8-K
| Quarterly results |
| 03/03/2020 |
8-K
| Quarterly results |
| 11/05/2019 |
8-K
| Quarterly results|
Docs:
|
"VIVUS Reports Third Quarter 2019 Financial Results Company to host conference call today at 4:30pm ET CAMPBELL, CA., November 5, 2019 - VIVUS, Inc. , a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended September 30, 2019 and provided a business update. “The strategies that we have implemented over the past several quarters continue to gain traction, as evidenced by growing patient adoption rates from our Qsymia Advantage Program, which increased 170% in prescriptions in the third quarter compared with the second quarter,” said John Amos, VIVUS' Chief Executive Officer. “As we implement our plan to expand the U..." |
|
| 08/06/2019 |
8-K
| Quarterly results |
| 04/30/2019 |
8-K
| Quarterly results|
Docs:
|
"VIVUS Reports First Quarter 2019 Financial Results Company to host conference call today at 4:30pm ET CAMPBELL, CA., April 30, 2019 - VIVUS, Inc. , a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended March 31, 2019 and provided a business update. “The first quarter of 2019 represents the completion of the third quarter of our ten-quarter turnaround,” said John Amos, Chief Executive Officer at VIVUS. “After successfully stabilizing the business in the third and fourth quarters of 2018, we made important progress in the first quarter of 2019 toward establishing a solid base for future growth. This included the r..." |
|
| 02/26/2019 |
8-K
| Quarterly results |
| 11/01/2018 |
8-K
| Quarterly results|
Docs:
|
"VIVUS Reports Third Quarter 2018 Financial Results Company to host conference call today at 4:30pm ET CAMPBELL, CA., November 1, 2018 - VIVUS, Inc. , a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended September 30, 2018 and provided a business update. “Our third quarter 2018 results are the first full quarter under our newly integrated management team and we are pleased with our improved financial performance,” said John Amos, Chief Executive Officer at VIVUS. “Earlier this year, we announced a set of initiatives geared toward executing on our business strategy to improve our financial structure and commercia..." |
|
| 08/07/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 03/13/2018 |
8-K
| Quarterly results|
Docs:
|
"VIVUS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS CAMPBELL, CA., March 13, 2018 — VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update. “Throughout 2017, we executed on strategies intended to expand our pipeline and maximize our legacy assets. Achievements in these areas include advancing tacrolimus toward the clinic, with a phase 2 trial start scheduled for the second half of 2018, and our marketing agreement for Qsymia® in the Republic of Korea,” said Thomas B. King, VIVUS' interim Chief Executive Officer. “We move into 2018 with continued eff..." |
|
| 11/07/2017 |
8-K
| Quarterly results |
| 08/03/2017 |
8-K
| Quarterly results|
Docs:
|
"VIVUS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS CAMPBELL, CA., August 3, 2017 - VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended June 30, 2017 and provided a business update. “During the second quarter, we made important progress in ramping up development of tacrolimus, our lead clinical candidate, which we believe has significant potential in treating pulmonary arterial hypertension, and we remain on track to hold a pre-IND meeting with FDA in the second half of this year,” said Seth H. Z. Fischer, VIVUS' Chief Executive Officer. “VIVUS is dedicated to addressing the urgent therapeutic needs of ..." |
|
| 05/03/2017 |
8-K
| Form 8-K - Current report |
| 03/08/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 05/03/2016 |
8-K
| Quarterly results |
| 03/09/2016 |
8-K
| Form 8-K - Current report |
| 11/04/2015 |
8-K
| Quarterly results |
| 08/05/2015 |
8-K
| Quarterly results |
| 07/30/2015 |
8-K
| Quarterly results |
| 05/05/2015 |
8-K
| Quarterly results |
| 02/24/2015 |
8-K
| Quarterly results |
| 11/05/2014 |
8-K
| Quarterly results |
| 08/07/2014 |
8-K
| Quarterly results |
| 05/05/2014 |
8-K
| Quarterly results |
| 02/24/2014 |
8-K
| Quarterly results |
| 11/05/2013 |
8-K
| Form 8-K - Current report |
| 08/06/2013 |
8-K
| Form 8-K - Current report |
| 05/08/2013 |
8-K
| Form 8-K - Current report |
| 02/25/2013 |
8-K
| Form 8-K - Current report |
| 11/06/2012 |
8-K
| Quarterly results |
| 08/07/2012 |
8-K
| Form 8-K - Current report |
| 05/07/2012 |
8-K
| Form 8-K - Current report |
| 02/28/2012 |
8-K
| Quarterly results |
|
|
|